NasdaqGM:XNCRBiotechs
Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent Extension - What's Changed
Xencor, Inc. recently announced that the U.S. Patent and Trademark Office issued U.S. Patent 12,492,253, extending protection for its Xtend Fc domain used to prolong the half-life of antibodies targeting C5 through December 2028.
This extension lengthens the U.S. royalty term for Ultomiris by around three years, enhancing visibility on a key royalty stream that Xencor expects will help fund its internal pipeline and innovation efforts.
We’ll now examine how the extended Ultomiris royalty...